BOLD Profile
Boundless Bio, Inc. is a clinical-stage oncology company specializing in the development of innovative cancer therapeutics designed to address the significant unmet medical needs of patients with oncogene-amplified tumors. The company's primary focus is on targeting extrachromosomal DNA (ecDNA), a critical driver of cancer progression and resistance. By targeting these DNA elements, Boundless Bio aims to disrupt the mechanisms that enable tumors to grow and resist treatment, offering new hope for patients with challenging cancers.
The company’s lead product candidate, BBI-355, is an oral inhibitor of checkpoint kinase 1 (CHK1), currently undergoing Phase 1/2 clinical trials. BBI-355 is designed to target tumors with oncogene amplification, a common genetic alteration associated with aggressive cancer types and poor patient outcomes. The Phase 1/2 trials are assessing the safety, tolerability, and efficacy of BBI-355 in treating various cancers that exhibit this genetic profile.
In addition to BBI-355, Boundless Bio is advancing BBI-825, an oral inhibitor of ribonucleotide reductase (RNR). BBI-825 is in Phase 1/2 clinical trials and targets cancer patients with resistance gene amplifications. This drug aims to address resistance mechanisms that limit the effectiveness of existing treatments, potentially providing a new therapeutic option for patients with drug-resistant cancers. The company is also progressing with its ecDTx 3 program, which targets a kinesin protein involved in the segregation of ecDNA during cell division, further advancing its commitment to tackling ecDNA-driven malignancies.
Originally known as Pretzel Therapeutics, Inc., Boundless Bio, Inc. rebranded in July 2019 to reflect its expanded focus and innovative approach to oncology. Founded in 2018, the company is headquartered in San Diego, California, and continues to build a robust pipeline of drug candidates aimed at improving outcomes for cancer patients worldwide.
|
